Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.
Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA; CONDOR Study Group. Morris MJ, et al. Among authors: piert m. Clin Cancer Res. 2021 Jul 1;27(13):3674-3682. doi: 10.1158/1078-0432.CCR-20-4573. Epub 2021 Feb 23. Clin Cancer Res. 2021. PMID: 33622706 Free PMC article. Clinical Trial.
Synthesis of 225Ac-PSMA-617 for Preclinical Use.
Dumond ARS, Rodnick ME, Piert MR, Scott PJH. Dumond ARS, et al. Among authors: piert mr. Curr Radiopharm. 2022;15(2):96-103. doi: 10.2174/1874471014666210709094616. Curr Radiopharm. 2022. PMID: 34250876
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Edwards DM, Schonewolf CA, Rice JD, Schipper M, Haken RKT, Matuszak M, Balter J, Jarema D, Arenberg DA, Piert M, Qin A, Kalemkerian GP, Schneider BJ, Ramnath N, Chapman CH, Elliott DA, Lawrence TS, Hearn J, Hayman JA, Jolly S. Edwards DM, et al. Among authors: piert m. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1332-1343. doi: 10.1016/j.ijrobp.2024.06.018. Epub 2024 Jul 4. Int J Radiat Oncol Biol Phys. 2024. PMID: 38971385 Clinical Trial.
Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.
Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, Henning TD, Wels WS, Uherek C, Rummeny EJ, Daldrup-Link HE. Meier R, et al. Among authors: piert m. Nucl Med Biol. 2008 Jul;35(5):579-88. doi: 10.1016/j.nucmedbio.2008.02.006. Epub 2008 May 2. Nucl Med Biol. 2008. PMID: 18589302
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.
Kong FS, Hu C, Pryma DA, Duan F, Matuszak M, Xiao Y, Ten Haken R, Siegel MJ, Hanna L, Curran WJ, Dunphy M, Gelblum D, Piert M, Jolly S, Robinson CG, Quon A, Loo BW, Srinivas S, Videtic GM, Faria SL, Ferguson C, Dunlap NE, Kundapur V, Paulus R, Siegel BA, Bradley JD, Machtay M. Kong FS, et al. Among authors: piert m. J Clin Oncol. 2024 Nov 20;42(33):3935-3946. doi: 10.1200/JCO.24.00022. Epub 2024 Oct 4. J Clin Oncol. 2024. PMID: 39365957 Clinical Trial.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
90 results